8UDV

The X-RAY co-crystal structure of human FGFR3 V555M and Compound 17


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.35 Å
  • R-Value Free: 0.261 
  • R-Value Work: 0.236 
  • R-Value Observed: 0.237 

wwPDB Validation   3D Report Full Report


Ligand Structure Quality Assessment 


This is version 1.1 of the entry. See complete history


Literature

Discovery of KIN-3248, An Irreversible, Next Generation FGFR Inhibitor for the Treatment of Advanced Tumors Harboring FGFR2 and/or FGFR3 Gene Alterations.

Tyhonas, J.S.Arnold, L.D.Cox, J.M.Franovic, A.Gardiner, E.Grandinetti, K.Kania, R.Kanouni, T.Lardy, M.Li, C.Martin, E.S.Miller, N.Mohan, A.Murphy, E.A.Perez, M.Soroceanu, L.Timple, N.Uryu, S.Womble, S.Kaldor, S.W.

(2024) J Med Chem 67: 1734-1746

  • DOI: https://doi.org/10.1021/acs.jmedchem.3c01819
  • Primary Citation of Related Structures:  
    8UDT, 8UDU, 8UDV

  • PubMed Abstract: 

    Fibroblast growth factor receptor (FGFR) alterations are present as oncogenic drivers and bypass mechanisms in many forms of cancer. These alterations can include fusions, amplifications, rearrangements, and mutations. Acquired drug resistance to current FGFR inhibitors often results in disease progression and unfavorable outcomes for patients. Genomic profiling of tumors refractory to current FGFR inhibitors in the clinic has revealed several acquired driver alterations that could be the target of next generation therapeutics. Herein, we describe how structure-based drug design (SBDD) was used to enable the discovery of the potent and kinome selective pan-FGFR inhibitor KIN-3248 , which is active against many acquired resistance mutations. KIN-3248 is currently in phase I clinical development for the treatment of advanced tumors harboring FGFR2 and/or FGFR3 gene alterations.


  • Organizational Affiliation

    Kinnate Biopharma, San Diego, California 92130, United States.


Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Fibroblast growth factor receptor 3
A, B, C
297Homo sapiensMutation(s): 1 
Gene Names: FGFR3JTK4
EC: 2.7.10.1
UniProt & NIH Common Fund Data Resources
Find proteins for P22607 (Homo sapiens)
Explore P22607 
Go to UniProtKB:  P22607
GTEx:  ENSG00000068078 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP22607
Sequence Annotations
Expand
  • Reference Sequence
Small Molecules
Ligands 3 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
WIQ (Subject of Investigation/LOI)
Query on WIQ

Download Ideal Coordinates CCD File 
F [auth A],
J [auth B],
N [auth C]
3-[(6-chloro-1-cyclopropyl-1H-benzimidazol-5-yl)ethynyl]-1-[(3S,5S)-5-(methoxymethyl)-1-(prop-2-enoyl)pyrrolidin-3-yl]-5-(methylamino)-1H-pyrazole-4-carboxamide
C26 H30 Cl N7 O3
ZYRPDGRQBLKEPY-ZWKOTPCHSA-N
SO4
Query on SO4

Download Ideal Coordinates CCD File 
D [auth A]
E [auth A]
G [auth A]
H [auth B]
I [auth B]
D [auth A],
E [auth A],
G [auth A],
H [auth B],
I [auth B],
K [auth C],
L [auth C]
SULFATE ION
O4 S
QAOWNCQODCNURD-UHFFFAOYSA-L
EDO
Query on EDO

Download Ideal Coordinates CCD File 
M [auth C]1,2-ETHANEDIOL
C2 H6 O2
LYCAIKOWRPUZTN-UHFFFAOYSA-N
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.35 Å
  • R-Value Free: 0.261 
  • R-Value Work: 0.236 
  • R-Value Observed: 0.237 
  • Space Group: C 1 2 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 170.664α = 90
b = 54.513β = 120.22
c = 128.718γ = 90
Software Package:
Software NamePurpose
BUSTERrefinement
autoPROCdata reduction
Aimlessdata scaling
PHASERphasing

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
Not funded--

Revision History  (Full details and data files)

  • Version 1.0: 2024-02-07
    Type: Initial release
  • Version 1.1: 2024-02-21
    Changes: Database references